Management of wheeze in pre-school children


Prof Colin Robertson,

Respiratory Medicine,

Royal Children's Hospital, Melbourne

General Practitioner encounters for asthma


Asthma-related general practice encounters, per 100 population, by age group, Australia, 1998–2002




Asthma in Australia, 2003

Emergency Dept attendances for asthma

Emergency Department presentations for asthma, per 100,000 population, by month and age group, New South Wales, January 1998 to March 2003



Asthma admissions, Australia 1992-2002



Is it asthma

Approach to treatment Acute episode Regular treatment

Outcome

Differential diagnosis – pre-school years

- bronchiolitis
- transient infant wheeze
- recurrent post infective cough
- cystic fibrosis
- \Box aspiration 1^o or 2^o
- cardiac failure
- structural abnormalities
- □ foreign body

Transient infant wheeze

- approx 2/3 of recurrent infant wheezing
- reduced lung function in infancy
- no associated atopy
- no family history of atopic disease
- maternal smoking major risk factor
- unlikely to respond to asthma therapy
- resolves spontaneously by 2-3 years

Differential diagnosis – pre-school years

- bronchiolitis
- transient infant wheeze
- recurrent post infective cough
- cystic fibrosis
- \Box aspiration 1^o or 2^o
- cardiac failure
- structural abnormalities
- □ foreign body

Recurrent non-specific (post viral) cough

- common in pre-school children
- paroxysmal cough asymptomatic between paroxysms
- night > day
- triggered by urti
- duration 2-4 weeks
- not associated with wheeze
- not responsive to asthma therapy

Differential diagnosis – pre-school years

- bronchiolitis
- transient infant wheeze
- recurrent post infective cough
- cystic fibrosis
- \Box aspiration 1^o or 2^o
- cardiac failure
- structural abnormalities
- □ foreign body

Temporal pattern of wheeze

Episodic (viral) wheeze

Wheezing during discrete time periods, often in association with clinical evidence of a viral cold, with absence of wheeze between episodes

Multiple-trigger wheeze

Wheezing that shows discrete exacerbations, but also symptoms between episodes

Patterns of wheeze in children

intermittent ~ 75-85% (Episodic viral wheeze)

persistent ~ 10-15%

Acute episodes of wheeze in the pre-school child

Viral associated wheeze

independent of asthmaexacerbation of asthma

Viral infection in wheezing exacerbations in children

- viruses identified in up to 85% of wheezing exacerbations, in children:
 - Rhinovirus, Coronavirus, Influenza virus, Parainfluenza virus, Respiratory syncytial virus (RSV)

seasonal correlations between rates of upper respiratory tract infections (URTIs) and hospital admissions for asthma

> Johnston SL BMJ 1995 Pattemore PK et al. Clin Exp Allergy 1992

Viral associated wheeze - therapeutic options

inhaled β – agonists
 inhaled corticosteroids
 oral corticosteroids
 oral montelukast

Inhaled β – agonists

□ pMDI and spacer

children under 6 years 2-6 puffs

frequency – up to 2 hourly as needed

Inhaled corticosteroids

- doubling dose of regular ICS
 not effective
- intermittent ICS at standard dose
 - not effective
- intermittent high dose
 - Iess effective than OCS, associated with side effects
- Not recommended

Oral corticosteroids

- Parent initiated OCS (~1mg/kg)
 ineffective in pre-school children
 Emergency dept OCS (~1mg/kg)
 ineffective in pre-school children
- Cochrane review in older children
 effective in dose of 2mg/kg prednisolone
- Recommended for episode severe enough to require admission to hospital
 2mg/kg initial dose, 1mg/kgtherafter

Analysis 6.2. Comparison 6 Population, Outcome 2 Asthmatic Children Only.

Review: Early emergency department treatment of acute asthma with systemic corticosteroids

Comparison: 6 Population

Outcome: 2 Asthmatic Children Only



Placebo admission rate > 40%

Study or subgroup	CS	Placebo	Odds Ratio	Weight	Odds Ratio
	n/N	n/N	M-H,Random,95% Cl		M-H,Random,95% Cl
Connett 1994a	13/19	15/18	· · · · · · · · · · · · · · · · · · ·	14.4 %	0.43 [0.09, 2.09]
Connett 1994b	7/18	12/15	·	14.3 %	0.16 [0.03, 0.77]
Scarfone 1993	11/41	19/40	_ -	20.9 %	0.41 [0.16, 1.03]
Storr 1987	53/73	65/67	← ∮	15.0 %	0.08 [0.02, 0.36]
Tal 1990	4/17	4/13		13.9 %	0.69 [0.14, 3.52]
Wolfson 1994	17/42	15/46		21.5 %	1.41 [0.59, 3.36]
Total (95% CI)	210	199	-	100.0 %	0.40 [0.17, 0.94]
Total events: 105 (CS), 130) (Placebo)				
Heterogeneity: Tau ² = 0.7	l; Chi² = 13.65, df =	= 5 (P = 0.02); I ² =63%			
Test for overall effect: Z =	2.10 (P = 0.035)				
			0.1 0.2 0.5 1.0 2.0 5.0 10.0		
			CS therapy Placebo		

Pred 2mg/kg or 30mg<5, 60mg >5, Methylpred 2or4mg/kg

Oral corticosteroids

- Parent initiated OCS (~1mg/kg)
 ineffective in pre-school children
 Emergency dept OCS (~1mg/kg)
 ineffective in pre-school children
- Cochrane review in older children
 effective in dose of 2mg/kg prednisolone
- Recommended for episode severe enough to require admission to hospital
 2mg/kg initial dose, 1mg/kgtherafter

Oral montelukast

Intermittent use, commenced at the beginning of an episode


reduces symptoms

reduces health resource utilisation

Approach to preventive therapy

indicated for children with persistent asthma or multi-triggered wheeze


Approach to preventative therapy in pre-schoolchildren




PEAK study

□ recruited at 2-3 years

- at high risk of developing asthma continuing through childhood
- randomised to FP 100ug bd or placebo for 2 years
- drug then stopped and child followed for a further year



FEV₁ outcome over time to age 50



Thank you